Impacts of Cyclosporin A on clinical pregnancy outcomes of p
Rapid development in assisted reproductive technology (ART) has led to a surge in its popularity among target couples. However, elucidation on the molecular mechanism and effective solutions for a common problem posed by ART, namely transfer failure, is still lacking. Cyclosporin A (CsA) application can not improve clinical pregnancy outcomes in patients with a history of unexplained transfer failure in frozen-thawed embryo transfer (FET) cycles.

The new therapeutic potential of CsA, a typical immunosuppressant widely used in the treatment of rejection after organ transplantation, in recurrent pregnancy loss (RPL) patients may inspire some novel transfer failure therapies in the future. The study was aimed to further explore the clinical effects of CsA, this study investigated whether its application can improve clinical pregnancy outcomes in patients with a history of unexplained transfer failure in FET cycles.

Data from a retrospective cohort investigation were analyzed using binary logistic regression to explore the relationship between CsA treatment and clinical pregnancy outcomes; the odds ratios and 95?% confidence intervals (CIs) were calculated as a measure of relevancy. Implantation rate was the main outcome measure.

There was no difference in the fine adjusted OR of the implantation rate, clinical pregnancy rate, chemical pregnancy rate, take-home baby rate, multiple births rate, preterm birth, abnormal birth weight, or sex ratio between the CsA-treated group and control group. No birth defects were observed in the present study.

In conclusion, although CsA does not affect infant characteristics, it has no beneficial effects on the clinical pregnancy outcomes in patients with a history of unexplained transfer failure in FET cycles.

Reproductive Biology and Endocrinology
Source: https://doi.org/10.1186/s12958-021-00728-x
1 share
Like
Comment
Share